Evidence map›Paper›PMID 36104358›Full record

ArticleScientific reports2022

Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants.

D Florensa, J Mateo, R Spaimoc, C Miret, S Godoy, F Solsona, P Godoy

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

D FlorensaDepartment of Computer Science, University of Lleida, Jaume II 69, 25001, Lleida, Spain. didac.florensa@gencat.cat.
J MateoDepartment of Computer Science, University of Lleida, Jaume II 69, 25001, Lleida, Spain.
R SpaimocDepartment of Computer Science, University of Lleida, Jaume II 69, 25001, Lleida, Spain.
C MiretField Epidemiology, Lleida Biomedical Research Institute (IRB Lleida), Av. Alcalde Rovira Roure 80, 25198, Lleida, Spain.
S GodoyField Epidemiology, Lleida Biomedical Research Institute (IRB Lleida), Av. Alcalde Rovira Roure 80, 25198, Lleida, Spain.
F SolsonaDepartment of Computer Science, University of Lleida, Jaume II 69, 25001, Lleida, Spain.
P GodoyPopulation Cancer Registry, Santa Maria University Hospital, Av. Alcalde Rovira Roure 44, 25198, Lleida, Spain.
Universitat de Lleida · ESInstituto de Investigación Biomédica de Lleida · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New SARS-CoV-2 may pose problems in controlling the COVID-19 pandemic for public health. We aimed to assess and compare the symptoms and severity of cases due to the Alpha and Delta variant dominance periods, taking into account the effect of COVID-19 vaccination. A prospective epidemiological study of SARS-CoV-2 in Lleida was made to determine differences between Alpha and Delta variants periods. We assessed symptoms, specific comorbidities, sociodemographic information and vaccination status. Bivariate and logistic regression analyses were used to estimate the adjusted odds ratio (aOR) and 95% confidence intervals (CI) to investigate the relationship between symptoms and severity and the variants. Alpha variant period compared to the Delta showed an increased risk of ICU admission (aOR 2.0; 95% CI 1.2-2.3) and death (aOR 2.6; 95% CI 1.8-3.9) and cases were associated with people aged > 85 years (aOR 2.1; 95% CI 1.7-2.6) and partially vaccinated (aOR 5.6; 95% CI 3.2-9.9) and unvaccinated people (aOR 27.8; 95% CI 19.7-40.5). Fever, cough and vomiting were significantly associated with the Alpha variant compared to the Delta (aOR 1.6 (95% CI 1.5-1.7), 2.0 (95% CI 1.9-2.2) and 2.5 (95% CI 2.2-2.9, respectively). Our results show that the severity and profile of clinical symptoms varied according to the variant. The risk of ICU admission and death was higher in the Alpha period compared to the Delta as it affected the elderly and cases were less vaccinated.

Indexed as

COVID-19AgedCOVID-19 VaccinesHumansPandemicsProspective StudiesSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID36104358
PMCPMC9472714
OpenAlexW4295900756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.